# Promoting equity on licensing exams: Test accommodations for medical students with diabetes

**Authors:** Lucia McGeehan, Melanie J. Robbins, Daniel Jurich, Sydney Tucker, Fateen Ata, Fateen Ata

PMC · DOI: 10.1371/journal.pone.0340975 · PLOS One · 2026-02-20

## TL;DR

This study examines how the USMLE handles accommodation requests for medical students with diabetes, showing that most requests are quickly and fully approved.

## Contribution

The study provides population-level data on USMLE accommodation approvals for diabetes, challenging the perception of a burdensome process.

## Key findings

- The USMLE approves the vast majority of accommodation requests from examinees with diabetes in full or in part.
- Over 42% of accommodation requests are approved within one business day.
- Less than 1.1% of diabetes-related accommodation requests exceed the 60-business-day processing timeline.

## Abstract

In this article, we will provide information about the USMLE test accommodations process and present data on requests based on diabetes, including the number of requests and the types of accommodations requested and approved. This study summarizes population-level data from 2023 on examinees who requested accommodations on the USMLE due to diabetes, the most prevalent physical impairment cited in requests at the time of this study. The data show that USMLE approves the vast majority of accommodation requests in full and all requests in part from examinees with diabetes. The average processing time is relatively low compared to the communicated 60-business day timeline, with less than 1.1% of cases exceeding this threshold and 42.1% approved in one business day. We conclude by addressing misconceptions that the process for requesting accommodations for individuals with diabetes is arduous and burdensome.

## Linked entities

- **Diseases:** diabetes (MONDO:0005015)

## Full-text entities

- **Genes:** ATM (ATM serine/threonine kinase) [NCBI Gene 472] {aka AT1, ATA, ATC, ATD, ATDC, ATE}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, CMPK1 (cytidine/uridine monophosphate kinase 1) [NCBI Gene 51727] {aka CK, CMK, CMPK, UMK, UMP-CMPK, UMPK}
- **Diseases:** headache (MESH:D006261), hyperglycemia (MESH:D006943), epilepsy (MESH:D004827), blurred vision (MESH:D014786), physical impairments (MESH:D059445), hypoglycemia (MESH:D007003), irritability (MESH:D001523), chills (MESH:D023341), Diabetes (MESH:D003920), weakness (MESH:D018908), abdominal pain (MESH:D015746), weight loss (MESH:D015431), dizziness (MESH:D004244), anxiety (MESH:D001007), bruises (MESH:D003288), T2D (MESH:D003924), autoimmune disease (MESH:D001327), gestational diabetes (MESH:D016640), visual, hearing, psychiatric, and learning disabilities (MESH:D007859), fatigue (MESH:D005221), USMLE (MESH:D000069279), T1D (MESH:D003922), metabolic disorder (MESH:D008659), disabilities (MESH:D009069), trouble concentrating (MESH:C567712)
- **Chemicals:** PONE-D-25-24269 (-), glucose (MESH:D005947), blood glucose (MESH:D001786)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12923048/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12923048/full.md

## References

14 references — full list in the complete paper: https://tomesphere.com/paper/PMC12923048/full.md

---
Source: https://tomesphere.com/paper/PMC12923048